| Autor: |
Wolfe A; Department of Graduate Medical Education, 21878Abbott Northwestern Hospital, 5531Allina Health, Minneapolis, MN, USA., Phillips A; Department of Graduate Medical Education, 21878Abbott Northwestern Hospital, 5531Allina Health, Minneapolis, MN, USA., Tierney DM; Department of Graduate Medical Education, 21878Abbott Northwestern Hospital, 5531Allina Health, Minneapolis, MN, USA., Melamed R; Department of Critical Care, 21878Abbott Northwestern Hospital, 5531Allina Health, Minneapolis, MN, USA., Qadri G; Department of Internal Medicine, 21878Abbott Northwestern Hospital, 5531Allina Health, Minneapolis, MN, USA., Lillyblad M; Department of Pharmacy, 21878Abbott Northwestern Hospital, 5531Allina Health, Minneapolis, MN, USA., Smith C; Care Delivery Research, 5531Allina Health, Minneapolis, MN, USA., St Hill C; Care Delivery Research, 5531Allina Health, Minneapolis, MN, USA., Stenzel AE; Care Delivery Research, 5531Allina Health, Minneapolis, MN, USA., Beddow D; Department of Internal Medicine, 21878Abbott Northwestern Hospital, 5531Allina Health, Minneapolis, MN, USA., Kirven J; Department of Internal Medicine, 21878Abbott Northwestern Hospital, 5531Allina Health, Minneapolis, MN, USA., Kethireddy R; Department of Internal Medicine, 21878Abbott Northwestern Hospital, 5531Allina Health, Minneapolis, MN, USA., Patel L; Department of Internal Medicine, 21878Abbott Northwestern Hospital, 5531Allina Health, Minneapolis, MN, USA. |
| Abstrakt: |
Direct-acting oral anticoagulants (DOACs) are prescribed in the treatment of venous thromboembolism, including pulmonary embolism (PE). Evidence is limited regarding the outcomes and optimal timing of DOACs in patients with intermediate- or high-risk PE treated with thrombolysis. We conducted a retrospective analysis of outcomes among patients with intermediate- and high-risk PE who received thrombolysis, by choice of long-term anticoagulant agent. Outcomes of interest included hospital length of stay (LOS), intensive care unit LOS, bleeding, stroke, readmission, and mortality. Descriptive statistics were used to examine characteristics and outcomes among patients, by anticoagulation group. Patients receiving a DOAC (n = 53) had shorter hospital LOS compared to those in warfarin (n = 39) and enoxaparin (n = 10) groups (mean LOS 3.6, 6.3 and 4.5 days, respectively; P < .0001). This single institution retrospective study suggests DOAC initiation <48 h from thrombolysis may result in shorter hospital LOS compared to DOAC initiation ≥48 h ( P < .0001). Further larger studies with more robust research methodology are needed to address this important clinical question. |
